Abstract
Although thousands of articles on drug interactions have been published and numerous computerized screening systems have been developed, patients continue to suffer from adverse drug interactions. Possible methods for reducing the risk of drug interactions include improving the knowledge of health care providers, improving computerized screening systems, providing information on patient risk factors, increased use of pharmacogenetic information, more attention to drug administration risk factors, and improving patient education on drug interactions.
This is a preview of subscription content, log in via an institution to check access.
References
Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins, 2000.
Hansten PD, Horn JR. Drug interactions analysis and management, St. Louis, Missouri, Facts & Comparisons, 2002.
Hazlet TK, Lee TA, Hansten PD, Horn, JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc 2001; 41: 200–4.
Chrischilles EA, Fulda TR, Byrns PJ, Winckler SC, Rupp MT, Chui MA. The role of pharmacy computer systems in preventing medication errors. J Am Pharm Assoc 2002; 42: 439–48.
Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343–70.
Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40:568–73.
Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc 2001; 41: 161–165.
Peterson JF, Bates DW. Preventable medication errors: identifying and eliminating serious drug interactions. J Am Pharm Assoc 2001; 41: 159–60.
Doucet J, Chassange P, Trivalle C, Landrin I, Pauty MD, Kadri N et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 1996; 44: 944–8.
Orloff DG. Label changes for Simvastatin (Zocor). US Food and Drug Administration, 2002.
Mulder AB, van Lijf HJ, Bon MA, van den Bergh FA, Touw DJ, Neef C, Vermes I. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70: 546–51.
Rogers JD, Zhao J, Liu L, Amin RD, Gagliano KD, Porras AG et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3–hydroxy-3–methylglutaril coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999; 66: 358–66.
Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 3 97–402.
Sugimoto K, Ohmori M, Tsuroka S, Nishiki K, Kawaguchi A, Harada K et al. Different effects of St. John's Wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70: 518–24.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hansten, P. Drug interaction management. Pharm World Sci 25, 94–97 (2003). https://doi.org/10.1023/A:1024077018902
Issue Date:
DOI: https://doi.org/10.1023/A:1024077018902